Free Trial
NYSE:GRDN

Guardian Pharmacy Services (GRDN) Stock Price, News & Analysis

$22.12 +0.85 (+4.00%)
(As of 11:41 AM ET)

About Guardian Pharmacy Services Stock (NYSE:GRDN)

Key Stats

Today's Range
$21.69
$22.61
50-Day Range
N/A
52-Week Range
$14.16
$23.05
Volume
57,653 shs
Average Volume
151,428 shs
Market Capitalization
$1.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.00
Consensus Rating
Buy

Company Overview

Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.

Guardian Pharmacy Services Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
10th Percentile Overall Score

GRDN MarketRank™: 

Guardian Pharmacy Services scored higher than 10% of companies evaluated by MarketBeat, and ranked 926th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Guardian Pharmacy Services has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Guardian Pharmacy Services has only been the subject of 3 research reports in the past 90 days.

  • Read more about Guardian Pharmacy Services' stock forecast and price target.
  • Short Interest

    There is no current short interest data available for GRDN.
  • Dividend Yield

    Guardian Pharmacy Services does not currently pay a dividend.

  • Dividend Growth

    Guardian Pharmacy Services does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for GRDN.
  • News Sentiment

    Guardian Pharmacy Services has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Guardian Pharmacy Services this week, compared to 3 articles on an average week.
  • Search Interest

    Only 2 people have searched for GRDN on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Guardian Pharmacy Services to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
Receive GRDN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Guardian Pharmacy Services and its competitors with MarketBeat's FREE daily newsletter.

GRDN Stock News Headlines

JD Vance Predicts: Wall Street vs. Trump & Your Money
Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
Guardian Pharmacy price target raised to $24 from $22 at Truist
Guardian Pharmacy reports Q3 adjusted EBITDA $23.0M, up 20% y/y
Guardian Pharmacy sees FY24 revenue $1.205B-$1.215B, consensus $1.19B
See More Headlines

GRDN Stock Analysis - Frequently Asked Questions

Guardian Pharmacy Services' stock was trading at $17.75 at the beginning of 2024. Since then, GRDN stock has increased by 26.1% and is now trading at $22.38.
View the best growth stocks for 2024 here
.

Guardian Pharmacy Services, Inc. (NYSE:GRDN) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($2.00) earnings per share for the quarter, missing analysts' consensus estimates of $0.19 by $2.19. The company earned $314.39 million during the quarter, compared to the consensus estimate of $303.21 million.

Guardian Pharmacy Services (GRDN) raised $102 million in an initial public offering on Thursday, September 26th 2024. The company issued 6,800,000 shares at a price of $14.00-$16.00 per share. Raymond James, Stifel and Truist Securities served as the underwriters for the IPO.

Guardian Pharmacy Services' quiet period expired on Tuesday, November 5th. Guardian Pharmacy Services had issued 8,000,000 shares in its initial public offering on September 26th. The total size of the offering was $112,000,000 based on an initial share price of $14.00. During Guardian Pharmacy Services' quiet period, underwriters and any insiders that worked on the IPO were restricted from issuing any research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Guardian Pharmacy Services' top institutional shareholders include Wellington Management Group LLP (0.81%), Allspring Global Investments Holdings LLC (0.52%), Maven Securities LTD (0.29%) and Seven Grand Managers LLC (0.24%). Insiders that own company stock include Thomas J Salentine Jr and Steven D Cosler.
View institutional ownership trends
.

Shares of GRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Guardian Pharmacy Services investors own include UnitedHealth Group (UNH) and Meta Platforms (META).

Company Calendar

Last Earnings
11/12/2024
Today
11/21/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/11/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Drug stores & proprietary stores
Sub-Industry
N/A
Fax
N/A
Employees
3,200
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$22.00
High Stock Price Target
$24.00
Low Stock Price Target
$21.00
Potential Upside/Downside
+3.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$1.32 billion
Optionable
N/A
Beta
N/A
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NYSE:GRDN) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners